Completed NA INTERVENTIONAL 3-arm NCT03111420

Study of AggreGuide A-100 (ADP) Assay

Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs

Sponsor: Aggredyne, Inc.

Conditions Platelet Dysfunction Due to Drugs Risk Factor, Cardiovascular

Interventions P2Y12 inhibitor Platelet function test

Updated 7 times since 2017 Last updated: Feb 20, 2019 Started: Jan 9, 2017 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Platelet Dysfunction Due to Drugs and Risk Factor, Cardiovascular and is currently completed. Aggredyne, Inc. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Feb 2020 — Jan 2021 [monthly]

Completed NA
Mar 2019 — Feb 2020 [monthly]

Completed NA

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Mar 2019 [monthly]

Active Not Recruiting NA

Status: Enrolling By Invitation → Active Not Recruiting
May 2017 — Jun 2018 [monthly]

Enrolling By Invitation NA

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aggredyne, Inc.

Data source: Aggredyne, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.